Form 4: BioMarin Executive George Eric Davis Executes Stock Option and Sells Shares
SEC Form 4 Filing
EVP and Chief Legal Officer of BioMarin Pharmaceutical, George Eric Davis, exercised stock options and sold shares on May 28, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 28, 2024, George Eric Davis, the EVP and Chief Legal Officer of BioMarin Pharmaceutical Inc., executed a transaction involving the company's stock.
- Davis exercised stock options to acquire 40,850 shares of common stock at a price of $63.10 per share.
- Simultaneously, Davis sold 38,071 shares at a weighted average price of $74.455, with prices ranging from $74.12 to $74.99.
- An additional 2,779 shares were sold at a weighted average price of $75.288, with prices ranging from $75.00 to $75.735.
- These transactions were executed under a 10b5-1 trading plan established on September 13, 2023.
- Following these transactions, Davis directly owns 56,157 shares of BioMarin common stock and holds options for 0 shares from this specific stock option grant.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions executed under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. These transactions are closely watched by investors for signals about management's confidence in the company's future prospects.
Comparison to Industry Standards
- Executive compensation practices, including stock options and sales, are common across the pharmaceutical industry.
- Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also utilize stock options as part of their executive compensation packages.
- The use of 10b5-1 trading plans is a standard practice to ensure compliance with insider trading regulations.
- The size and frequency of these transactions can vary based on the individual's holdings and the company's compensation policies.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2014-12-04 | Date stock options were granted. |
| 2023-09-13 | Date of execution of the 10b5-1 plan. |
| 2024-05-28 | Date of the stock option exercise and share sales. |
| 2024-05-30 | Date of signature on the SEC filing. |
| 2024-06-30 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.